Schroder Investment Management Group I Mab Transaction History

Schroder Investment Management Group

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$1.21 - $1.9 $375,703 - $589,948	310,499 New	310,499 $589,000
Q2 2022 Aug 11, 2022	BUY	$8.27 - $18.43 $1.55 Million - $3.45 Million	187,046 Added 305.43%	248,287 $2.7 Million
Q1 2022 May 16, 2022	BUY	$12.54 - $46.93 $208,377 - $779,835	16,617 Added 37.24%	61,241 $1.16 Million
Q4 2021 Feb 14, 2022	BUY	$45.28 - $74.5 $1.03 Million - $1.69 Million	22,691 Added 103.46%	44,624 $919,000
Q3 2021 Nov 12, 2021	SELL	$57.18 - $84.43 $147,581 - $217,913	-2,581 Reduced 10.53%	21,933 $691,000
Q2 2021 Aug 13, 2021	BUY	$47.86 - $83.95 $1.17 Million - $2.06 Million	24,514 New	24,514 $2.06 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $74.8M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

Stay updated on Schroder Investment Management Group with notifications on news.